152 related articles for article (PubMed ID: 19067765)
1. Valproic acid blocks adhesion of renal cell carcinoma cells to endothelium and extracellular matrix.
Jones J; Juengel E; Mickuckyte A; Hudak L; Wedel S; Jonas D; Hintereder G; Blaheta RA
J Cell Mol Med; 2009 Aug; 13(8B):2342-2352. PubMed ID: 19067765
[TBL] [Abstract][Full Text] [Related]
2. The histone deacetylase inhibitor valproic acid alters growth properties of renal cell carcinoma in vitro and in vivo.
Jones J; Juengel E; Mickuckyte A; Hudak L; Wedel S; Jonas D; Blaheta RA
J Cell Mol Med; 2009 Aug; 13(8B):2376-2385. PubMed ID: 18657224
[TBL] [Abstract][Full Text] [Related]
3. Effects of combined valproic acid and the epidermal growth factor/vascular endothelial growth factor receptor tyrosine kinase inhibitor AEE788 on renal cell carcinoma cell lines in vitro.
Juengel E; Engler J; Mickuckyte A; Jones J; Hudak L; Jonas D; Blaheta RA
BJU Int; 2010 Feb; 105(4):549-57. PubMed ID: 19594733
[TBL] [Abstract][Full Text] [Related]
4. Alterations of the gene expression profile in renal cell carcinoma after treatment with the histone deacetylase-inhibitor valproic acid and interferon-alpha.
Juengel E; Bhasin M; Libermann T; Barth S; Michaelis M; Cinatl J; Jones J; Hudak L; Jonas D; Blaheta RA
World J Urol; 2011 Dec; 29(6):779-86. PubMed ID: 20640575
[TBL] [Abstract][Full Text] [Related]
5. Resistance after chronic application of the HDAC-inhibitor valproic acid is associated with elevated Akt activation in renal cell carcinoma in vivo.
Juengel E; Makarević J; Tsaur I; Bartsch G; Nelson K; Haferkamp A; Blaheta RA
PLoS One; 2013; 8(1):e53100. PubMed ID: 23372654
[TBL] [Abstract][Full Text] [Related]
6. Low dosed interferon alpha augments the anti-tumor potential of histone deacetylase inhibition on prostate cancer cell growth and invasion.
Hudak L; Tezeeh P; Wedel S; Makarević J; Juengel E; Tsaur I; Bartsch G; Wiesner C; Haferkamp A; Blaheta RA
Prostate; 2012 Dec; 72(16):1719-35. PubMed ID: 22473339
[TBL] [Abstract][Full Text] [Related]
7. Valproic acid sensitizes metformin-resistant human renal cell carcinoma cells by upregulating H3 acetylation and EMT reversal.
Wei M; Mao S; Lu G; Li L; Lan X; Huang Z; Chen Y; Zhao M; Zhao Y; Xia Q
BMC Cancer; 2018 Apr; 18(1):434. PubMed ID: 29665787
[TBL] [Abstract][Full Text] [Related]
8. Altered expression of beta1 integrins in renal carcinoma cell lines exposed to the differentiation inducer valproic acid.
Oertl A; Relja B; Makarevic J; Weich E; Höfler S; Jones J; Jonas D; Bratzke H; Baer PC; Blaheta RA
Int J Mol Med; 2006 Aug; 18(2):347-54. PubMed ID: 16820945
[TBL] [Abstract][Full Text] [Related]
9. New histone deacetylase inhibitors as potential therapeutic tools for advanced prostate carcinoma.
Wedel SA; Sparatore A; Soldato PD; Al-Batran SE; Atmaca A; Juengel E; Hudak L; Jonas D; Blaheta RA
J Cell Mol Med; 2008 Dec; 12(6A):2457-66. PubMed ID: 18266964
[TBL] [Abstract][Full Text] [Related]
10. Combining the receptor tyrosine kinase inhibitor AEE788 and the mammalian target of rapamycin (mTOR) inhibitor RAD001 strongly inhibits adhesion and growth of renal cell carcinoma cells.
Juengel E; Engler J; Natsheh I; Jones J; Mickuckyte A; Hudak L; Jonas D; Blaheta RA
BMC Cancer; 2009 May; 9():161. PubMed ID: 19473483
[TBL] [Abstract][Full Text] [Related]
11. Intensified antineoplastic effect by combining an HDAC-inhibitor, an mTOR-inhibitor and low dosed interferon alpha in prostate cancer cells.
Tsaur I; Hudak L; Makarević J; Juengel E; Mani J; Borgmann H; Gust KM; Schilling D; Bartsch G; Nelson K; Haferkamp A; Blaheta RA
J Cell Mol Med; 2015 Aug; 19(8):1795-804. PubMed ID: 25808196
[TBL] [Abstract][Full Text] [Related]
12. Impact of combined HDAC and mTOR inhibition on adhesion, migration and invasion of prostate cancer cells.
Wedel S; Hudak L; Seibel JM; Makarević J; Juengel E; Tsaur I; Wiesner C; Haferkamp A; Blaheta RA
Clin Exp Metastasis; 2011 Jun; 28(5):479-91. PubMed ID: 21452015
[TBL] [Abstract][Full Text] [Related]
13. [Preclinical studies on the influence of the tyrosine kinase inhibitor AEE788 on malignant properties of renal cell carcinoma cells].
Wedel SA; Mickuckyte A; Juengel E; Jones J; Hudak L; Jonas D; Blaheta RA
Urologe A; 2008 Sep; 47(9):1175-81. PubMed ID: 18688594
[TBL] [Abstract][Full Text] [Related]
14. Combination of metformin and valproic acid synergistically induces cell cycle arrest and apoptosis in clear cell renal cell carcinoma.
Zhang X; Zhang X; Huang T; Geng J; Liu M; Zheng J
Int J Clin Exp Pathol; 2015; 8(3):2823-8. PubMed ID: 26045790
[TBL] [Abstract][Full Text] [Related]
15. Critical analysis of simultaneous blockage of histone deacetylase and multiple receptor tyrosine kinase in the treatment of prostate cancer.
Wedel S; Hudak L; Seibel JM; Juengel E; Oppermann E; Haferkamp A; Blaheta RA
Prostate; 2011 May; 71(7):722-35. PubMed ID: 20954195
[TBL] [Abstract][Full Text] [Related]
16. Combined Treatment with Valproic Acid and 5-Aza-2'-Deoxycytidine Synergistically Inhibits Human Clear Cell Renal Cell Carcinoma Growth and Migration.
Xi W; Chen X; Sun J; Wang W; Huo Y; Zheng G; Wu J; Li Y; Yang A; Wang T
Med Sci Monit; 2018 Feb; 24():1034-1043. PubMed ID: 29457966
[TBL] [Abstract][Full Text] [Related]
17. HDAC inhibition suppresses bladder cancer cell adhesion to collagen under flow conditions.
Juengel E; Meyer dos Santos S; Schneider T; Makarevic J; Hudak L; Bartsch G; Haferkamp A; Wiesner C; Blaheta RA
Exp Biol Med (Maywood); 2013 Nov; 238(11):1297-304. PubMed ID: 24006305
[TBL] [Abstract][Full Text] [Related]
18. Modulation of adhesion and growth of colon and pancreatic cancer cells by the histone deacetylase inhibitor valproic acid.
Jones J; Bentas W; Blaheta RA; Makarevic J; Hudak L; Wedel S; Probst M; Jonas D; Juengel E
Int J Mol Med; 2008 Sep; 22(3):293-9. PubMed ID: 18698487
[TBL] [Abstract][Full Text] [Related]
19. Molecular targeting of prostate cancer cells by a triple drug combination down-regulates integrin driven adhesion processes, delays cell cycle progression and interferes with the cdk-cyclin axis.
Wedel S; Hudak L; Seibel JM; Makarević J; Juengel E; Tsaur I; Waaga-Gasser A; Haferkamp A; Blaheta RA
BMC Cancer; 2011 Aug; 11():375. PubMed ID: 21867506
[TBL] [Abstract][Full Text] [Related]
20. Acetylation of histone H3 prevents resistance development caused by chronic mTOR inhibition in renal cell carcinoma cells.
Juengel E; Dauselt A; Makarević J; Wiesner C; Tsaur I; Bartsch G; Haferkamp A; Blaheta RA
Cancer Lett; 2012 Nov; 324(1):83-90. PubMed ID: 22579787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]